Drug – bio-affecting and body treating compositions – Extract – body fluid – or cellular material of undetermined... – Milk or colostrum
Reexamination Certificate
2003-08-22
2010-10-19
Kim, Taeyoon (Department: 1651)
Drug, bio-affecting and body treating compositions
Extract, body fluid, or cellular material of undetermined...
Milk or colostrum
C424S520000, C424S725000, C424S157100, C424S130100, C514S021800
Reexamination Certificate
active
07815943
ABSTRACT:
A composition for use in cardiovascular therapy includes transfer factor. The transfer factor may be nonmammalian transfer factor, such as that derived from eggs, or mammalian transfer factor, such as that derived from colostrum. The composition may also include one or more of the following: an LDL receptor-binding element; a blood flow-enhancing element; a cholesterol reducing element; a fat oxidation prevention element, and an antioxidant. Treatment methods include enlisting the immune system of a subject receiving therapy to attack pathogens that cause inflammation of blood vessels or to otherwise reduce inflammation of blood vessels.
REFERENCES:
patent: 4816563 (1989-03-01), Wilson et al.
patent: 5080895 (1992-01-01), Tokoro
patent: 5470835 (1995-11-01), Kirkpatrick et al.
patent: 5650418 (1997-07-01), Rath et al.
patent: 6022901 (2000-02-01), Goodman
patent: 6203818 (2001-03-01), Vester
patent: 6468534 (2002-10-01), Hennen et al.
patent: 6506413 (2003-01-01), Ramaekers
patent: 6693094 (2004-02-01), Pearson et al.
Cholesterol-lowering drugs (http://www.americanheart.org/presenter.jhtml?identifier=4510; p. 2).
Focant et al. The Effect of Vitamin E Supplementation of Cow Diets Containing Rapeseed and Linseed on the Prevention of Milk Fat Oxidation. J. Dairy Sci. 1998, 81:1095-1101, Abstract.
Tentolouris et al. L-Arginine in coronary atherosclerosis. Int. J. Cardiol., 2000,75(2-3):123-128.
Gordon Cardiovascular Research. Explore, 1999, http://www.explorepub.com/articles/heart—disease.html, p. 3.
Kirkpatrick Properties and activities of transfer factor. J. Allergy and Clin. Immunol. 1975, 55(6):411-421; Abstract.
Vercellotti. Microbes, inflammation and atherosclerosis: will old pathology lessons guide new therapies? Trans Am Clin. Climatol. Assoc. 2001, 112:215-222; Abstract.
Singh et al. Coenzyme Q in cardiovascular disease. J Assoc Physicians India. Mar. 1998;46(3):299-306; Abstract.
Campbell et al. 1998. Chlamydia pneumoniae and Cardiovascular Disease. Emerging Infectious Diseases. vol. 4, No. 4, October-December p. 571-579.
Kemper.1999. Ginger (Zingiber officinale). Longwood Herbal Task Force: http://www.mcp.edu/herbal/default.htm. p. 1-18.
Szapary et al. 2000. Alternative Medicine in Cardiovascular Disease: More Questions Than Answers. ACC Current Journal Review. p. 104-108.
Williamson et al. 1997. Herbal therapies:The facts and the fiction. Drug Topics. p. 78-87.
PCT International Search Report dated Mar. 19, 2004, Performed for Application PCT/US03.26427.
U.S. Appl. No. 60/423,965, filed Nov. 4, 2002, and entitled “Methods and Compositions for Focusing Cell-Mediated Immune Response and Enhancing Efficiency of an Individual's Antioxidant Profile, Detoxification Abilities, and General Cell and Molecular Health.”
4Life Research, LC
Durham Jones & Pinegar, IP Law Group
Kim Taeyoon
LandOfFree
Cardiovascular therapy composition including transfer factor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cardiovascular therapy composition including transfer factor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cardiovascular therapy composition including transfer factor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4201188